Literature DB >> 12465753

Prostate cancer gene therapy: past experiences and future promise.

Thomas A Gardner1, James Sloan, Sudhanshu P Raikwar, Chinghai Kao.   

Abstract

Gene therapy has been used to target prostate cancer with excellent pre-clinical efficacy but limited clinical efficacy. The concept of delivering genetic material to prostate cancer cells to alter their phenotype and ultimately their behavior has been demonstrated in the laboratory over the last decade. Translating those pre-clinical findings into novel therapies for prostate cancer has been difficult. The stigma of gene therapy and the aggressive regulation of clinical trials involving transfer of genetic material to patients are two major impediments to clinical successes in gene therapy. This review hopes to provide a snapshot of prior gene transfer protocol findings and forecast the exciting future directions investigators are heading.

Entities:  

Mesh:

Year:  2002        PMID: 12465753     DOI: 10.1023/a:1020875925685

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  2 in total

1.  Development of an immunotherapeutic adenovirus targeting hormone-independent prostate cancer.

Authors:  Jae Sik Kim; Sang Don Lee; Sang Jin Lee; Moon Kee Chung
Journal:  Onco Targets Ther       Date:  2013-11-12       Impact factor: 4.147

2.  Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.

Authors:  Bo-Rim Yi; Kyung-A Hwang; Yun-Bae Kim; Seung U Kim; Kyung-Chul Choi
Journal:  Int J Mol Sci       Date:  2012-09-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.